Centre for Molecular Medicine and Therapeutics
Encyclopedia
The Centre for Molecular Medicine and Therapeutics (CMMT) is part of the University of British Columbia
's Faculty of Medicine. The Centre is located at the Child & Family Research Institute (CFRI) in Vancouver, Canada. Research at the centre is focused on discovering genetic susceptibility to illnesses such as Huntington Disease, Type 2 diabetes and bipolar disorder
.
In 2008, the director and founder of the Centre, Dr. Michael Hayden, was named "Researcher of the Year" by the Canada Institutes of Health Research. In 2011, he was appointed to the Order of Canada in 2011 for his contributions to Huntington's Disease research.
Principal investigators within the Centre are involved in other initiatives. Dr. Daniel Goldowitz is the Scientific Director of NeuroDevNet, which is a Canada Networks of Centres of Excellence. The life sciences research laboratory consists of over 200 staff, nine of whom are UBC faculty members. Four of the principal investigators at the Centre are Canada Research Chairs.
In 1998, the current CMMT building, located at the Child & Family Research Institute on the BC Children’s and Women’s Hospital site was completed and the Transgenic Core Facility was established. During 1999 and 2000, the Scientific Stores Core Facility and the DNA Sequencing Core Facility were established.
Since 2000, CMMT has further expanded its facilities and services, including the addition of a Bioanalyzer Core Facility in 2003, expansion of the Transgenic Core Facility in 2005 and the establishment of the Genotype and Gene Expression Core Facility in 2006.
University of British Columbia
The University of British Columbia is a public research university. UBC’s two main campuses are situated in Vancouver and in Kelowna in the Okanagan Valley...
's Faculty of Medicine. The Centre is located at the Child & Family Research Institute (CFRI) in Vancouver, Canada. Research at the centre is focused on discovering genetic susceptibility to illnesses such as Huntington Disease, Type 2 diabetes and bipolar disorder
Bipolar disorder
Bipolar disorder or bipolar affective disorder, historically known as manic–depressive disorder, is a psychiatric diagnosis that describes a category of mood disorders defined by the presence of one or more episodes of abnormally elevated energy levels, cognition, and mood with or without one or...
.
In 2008, the director and founder of the Centre, Dr. Michael Hayden, was named "Researcher of the Year" by the Canada Institutes of Health Research. In 2011, he was appointed to the Order of Canada in 2011 for his contributions to Huntington's Disease research.
Principal investigators within the Centre are involved in other initiatives. Dr. Daniel Goldowitz is the Scientific Director of NeuroDevNet, which is a Canada Networks of Centres of Excellence. The life sciences research laboratory consists of over 200 staff, nine of whom are UBC faculty members. Four of the principal investigators at the Centre are Canada Research Chairs.
Key achievements
- 1999 – ABCA1ABCA1ATP-binding cassette transporter ABCA1 , also known as the cholesterol efflux regulatory protein is a protein which in humans is encoded by the ABCA1 gene...
a key regulator of HDL levels in humans is discovered - 2003 – LPL deficiency is cured in animal models
- 2004 – Open-access JASPAR database is released - a fundamental resource for studying gene regulation
- 2005 – Gene networks analysis algorithm published
- 2006 – Huntington Disease is prevented in mice
- 2006 – The genetic cause of codeine-induced adverse drug reaction causing infant death is identified
- 2006 – A new palmitoyl transferase that promotes protein folding and transport is identified
- 2007 – The contribution of cholesterol to diabetes is elucidated
- 2007 – New software for identifying DNA changes that alter the regulation of genes is created
- 2007 – A severe Adverse Drug ReactionAdverse drug reactionAn adverse drug reaction is an expression that describes harm associated with the use of given medications at a normal dosage. ADRs may occur following a single dose or prolonged administration of a drug or result from the combination of two or more drugs...
caused by normal doses of codeine is identified. - 2008 – A new gene associated with Bipolar DisorderBipolar disorderBipolar disorder or bipolar affective disorder, historically known as manic–depressive disorder, is a psychiatric diagnosis that describes a category of mood disorders defined by the presence of one or more episodes of abnormally elevated energy levels, cognition, and mood with or without one or...
is identified - 2008 – Genomics analysis of endosomal transport machinery is completed
- 2008 – Genetic Variants predictive of severe deafness in children receiving CisplatinCisplatinCisplatin, cisplatinum, or cis-diamminedichloroplatinum is a chemotherapy drug. It is used to treat various types of cancers, including sarcomas, some carcinomas , lymphomas, and germ cell tumors...
chemotherapy are identified - 2009 – Genetic Roots of Extreme Violence in Mice is identified
- 2009 – Researchers find potential treatment for Huntington Disease
- 2010 – Researchers discovers that drugs for Alzheimer’s may be a potential cure for Huntington’s
- 2010 – Discovery of new mechanism of brain cell injury in Huntington’s disease offers new approaches to treatment
- 2010 – Treatment with memantine leads to the reversal of the motor and neuropathological deficits and damage in late stages of animal models of HD, leading to a two phase clinical trial.
Corporate history
CMMT’s development started in the early nineties with an informal discussion between CMMT’s current Director, Dr. Michael Hayden, and Merck Frosst. In 1992, a $15 million commitment over five years from Merck Frosst Canada provided the initial funding for CMMT. The following year, in 1993, UBC Board of Governors and Senate approved CMMT as the first Centre in the Faculty of Medicine. That same year, the province of British Columbia pledged $9 million to build a dedicated building for CMMT.In 1998, the current CMMT building, located at the Child & Family Research Institute on the BC Children’s and Women’s Hospital site was completed and the Transgenic Core Facility was established. During 1999 and 2000, the Scientific Stores Core Facility and the DNA Sequencing Core Facility were established.
Since 2000, CMMT has further expanded its facilities and services, including the addition of a Bioanalyzer Core Facility in 2003, expansion of the Transgenic Core Facility in 2005 and the establishment of the Genotype and Gene Expression Core Facility in 2006.
Principal investigators
- Dr. Michael R. Hayden – Canada Research Chair Tier I & Professor, Department of Medical Genetics
- Dr. Elizabeth Conibear – Associate Professor, Department of Medical Genetics
- Dr. Daniel Goldowitz – Canada Research Chair Tier I & Professor, Department of Medical Genetics
- Dr. Michael S. Kobor – Assistant Professor, Department of Medical Genetics
- Dr. Blair R. Leavitt – Assistant Professor, Department of Medical Genetics
- Dr. Elizabeth M. Simpson – Canada Research Chair Tier II & Professor, Department of Medical Genetics
- Dr. Stefan Taubert – Canada Research Chair Tier II & Assistant Professor, Department of Medical Genetics
- Dr. Wyeth W. Wasserman – Professor, Department of Medical Genetics
Areas of research
- Bioinformatics
- Developmental Biology
- Epigenetics
- Lipid Biology
- Neurobiology
- Pharmacogenomics
- Transgenics